Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric, Retrospective, Real-Word Study to Evaluate the Efficacy and Safety of Inebilizumab Compare With Rituximab in Neuromyelitis Optica Spectrum Disorders

NCT06068829 is registered in ClinicalTrials.gov with Feng Jinzhou as lead sponsor.

NCT NCT06068829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06068829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric, Retrospective, Real-Word Study to Evaluate the Efficacy and Safety of Inebilizumab Compare With Rituximab in Neuromyelitis Optica Spectrum Disorders
Lead sponsor
Feng Jinzhou
Phase
Observational
Overall status
Unknown status
Start date
October 20, 2023
Completion date
June 30, 2025
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorders